

July 5, 2023

VIA EDGAR

Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jimmy McNamara

Re: DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed June 30, 2023 File No. 333-273068 Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, DiaMedica Therapeutics Inc. (the "Registrant") hereby respectfully requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time, on July 7, 2023, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Fox Rothschild LLP, counsel to the Registrant, to orally modify or withdraw this request for acceleration.

The Registrant requests that it be notified of such effectiveness by a telephone call to Amy Culbert of Fox Rothschild LLP at (612) 607-7287.

Thank you for your assistance in this matter. Should you have any questions, please call Ms. Culbert.

Very truly yours,

/s/ Rick Pauls

Rick Pauls President and Chief Executive Officer